Sana Biotechnology (SANA) Wells Fargo 21st Annual Healthcare Conference summary

Company overview and technology platforms

• Focus on scaling engineered cells for cell and gene therapy, targeting highly prevalent diseases.

• Lead program aims for a one-time treatment for type 1 diabetes using immune-evasive, gene-modified islets.

• Second platform enables cell-specific in vivo delivery, with initial application in CAR T therapy.

• Progress includes first human transplant of gene-modified islets without immunosuppression, showing 14 months of function.

• In vivo CAR T program (SG293) is advancing, with human trials planned in China, though facing regulatory delays.

SC451 program and clinical development

• IND filing for SC451, a gene-modified stem cell-derived islet therapy, is targeted for this year, with phase I/II to follow.

• GLP toxicology and non-clinical studies are nearly complete; tech transfer to GMP manufacturing is the main remaining step.

• Ongoing validation of release assays and supply chain integration are required before IND submission.

• Early clinical signals will focus on cell engraftment and immune evasion, with key data expected next year.

• If successful, rapid progression to registration studies is possible, with scalability and commercial model planning underway.

In vivo CAR T program and competitive landscape

• Program prioritizes cell specificity, DNA integration for expansion, and dissociation of entry from activation to improve safety.

• Uses CD8 for cell entry, aiming for more targeted delivery and reduced toxicity compared to CD3-based approaches.

• Oncology is the initial focus due to higher safety bar in autoimmune indications; rapid expansion to autoimmune possible if safety and efficacy are demonstrated.

• Dose finding in humans is critical due to limitations of animal models; early efficacy signals may be seen quickly after trial initiation.

• Competitive B-cell depleter landscape includes multiple modalities; early clinical data will clarify differentiation.